Payment overview · 2025
General Payments
$2,127.48
116 reported records · 24 companies
Healthcare provider profile · identity verified
Matthew David Jacobson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEWARK, DE · NPI 1346385507
Verified facts
What the public records show
CMS Open Payments records show Matthew David Jacobson, MD received $2,127.48 in general payments during 2025 across 116 reported records.
Novo Nordisk Inc accounted for 14.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $310.45 | 14.6% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $297.62 | 14.0% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $261.03 | 12.3% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $179.69 | 8.4% | 14 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $151.84 | 7.1% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $124.23 | 5.8% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $119.75 | 5.6% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $85.32 | 4.0% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $67.33 | 3.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.29 | 2.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.33 | 2.3% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $48.23 | 2.3% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $46.85 | 2.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $46.80 | 2.2% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.27 | 2.1% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.85 | 1.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $35.12 | 1.6% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $28.88 | 1.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.84 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.37 | 1.3% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $26.82 | 1.3% | 1 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.93 | 0.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.58 | 0.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.06 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,127.48 | 116 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $173.79 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $167.33 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $167.33 | 11 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $151.84 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $145.75 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $145.75 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $137.90 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $126.24 | 11 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $119.75 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $115.28 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $85.63 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $85.32 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $75.89 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $75.89 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $75.89 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $67.43 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $67.33 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $58.29 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $58.29 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $53.45 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $48.34 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.34 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $48.33 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $48.23 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $46.85 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $46.80 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $45.27 | 3 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $38.85 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $35.12 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $35.12 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.84 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.84 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $26.82 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $26.82 | 1 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 98 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 169 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
169 | 47 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
169 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
98 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 837 | 249 |
| Omeprazole | Omeprazole | 396 | 117 |
| Lisinopril | Lisinopril | 390 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 381 | 109 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 360 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 350 | 113 |
| Metformin Hcl | Metformin Hcl | 331 | 105 |
| Losartan Potassium | Losartan Potassium | 325 | 102 |
| Gabapentin | Gabapentin | 239 | 84 |
| Hydrochlorothiazide | Hydrochlorothiazide | 211 | 66 |
| Simvastatin | Simvastatin | 198 | 57 |
| Jardiance | Empagliflozin | 169 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 61 |
| Pravastatin Sodium | Pravastatin Sodium | 156 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 51 |
| Furosemide | Furosemide | 131 | 32 |
| Alprazolam | Alprazolam | 130 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 57 |
| Montelukast Sodium | Montelukast Sodium | 113 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 39 |
| Trazodone Hcl | Trazodone Hcl | 103 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 28 |
| Eliquis | Apixaban | 98 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 26 |
| Carvedilol | Carvedilol | 90 | 28 |
| Tramadol Hcl | Tramadol Hcl | 90 | 33 |
| Alendronate Sodium | Alendronate Sodium | 89 | 27 |
| Allopurinol | Allopurinol | 87 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 85 | 28 |
| Sertraline Hcl | Sertraline Hcl | 84 | 26 |
| Ozempic | Semaglutide | 82 | 19 |
| Ezetimibe | Ezetimibe | 78 | 22 |
| Januvia | Sitagliptin Phosphate | 78 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 25 |
| Lorazepam | Lorazepam | 75 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 29 |
| Bupropion Xl | Bupropion Hcl | 66 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 21 |
| Glimepiride | Glimepiride | 59 | 22 |
| Glipizide Er | Glipizide | 58 | 18 |
| Mirtazapine | Mirtazapine | 56 | 20 |
| Celecoxib | Celecoxib | 53 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 19 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 20 |
| Methylprednisolone | Methylprednisolone | 49 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 43 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 15 |
| Famotidine | Famotidine | 42 | 13 |
| Potassium Chloride | Potassium Chloride | 41 | 12 |
| Tradjenta | Linagliptin | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 11 |
| Xarelto | Rivaroxaban | 39 | 12 |
| Farxiga | Dapagliflozin Propanediol | 38 | 15 |
| Metformin Hcl Er | Metformin Hcl | 38 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Valsartan | Valsartan | 35 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 12 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Atenolol | Atenolol | 33 | 12 |
| Irbesartan | Irbesartan | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 29 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 19 |
| Meloxicam | Meloxicam | 29 | 13 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 23 |
| Valacyclovir | Valacyclovir Hcl | 24 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | 12 |
| Lactulose | Lactulose | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Prednisone | Prednisone | 22 | 17 |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Niacin Er | Niacin | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | 14 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,127.48 · 116 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AUSTEDO XR, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Flexitouch Plus, GARDASIL 9, JARDIANCE, MOUNJARO, NEXLETOL, NURTEC ODT, Nimbl, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, RECORLEV, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, VYKAT XR, Veozah, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error